35 research outputs found

    Demographic and clinical characteristics of the sample across BMI tertiles.

    Full text link
    <p>Data are percentages and means ± standard deviations. HADS = Hospital anxiety and depression scale.</p

    Logistic regression of presence of problems in mobility, self care and usual activities (EQ5D) and presence of anxiety and depression (HADS) by BMI tertiles and by continuous BMI.

    Full text link
    <p>Presence of problems defined as level 2 (some problems) and level 3 (extreme problems) scores on EQ5D-3L; Presence of anxiety and depression defined as HADS anxiety subscale score ≥8.</p><p>* P<0.05.</p><p>**P<0.001.</p><p>Model 1 adjusting for age and sex.</p><p>Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.</p

    Linear regression of BMI predicting IWQOL-Lite subscale and total scores and perceived health status (EQ5D-3L VAS) in whole sample and stratified by gender.

    Full text link
    <p>U.B.  = Unstandardized Beta, S.E.  = Standard error, S.B  = Standardised Beta.</p><p>*P<0.05, **P<0.001.</p><p>Model 1 adjusting for age, gender and interaction between BMI and gender.</p>†<p>Model 1 and 2 adjusting for age only.</p><p>Model 2 additionally adjusting for diabetes, hypertension, arthritis, obstructive sleep apnoea, cardiovascular disease.</p

    Risk of bias summary.

    Full text link
    <p>Review authors’ judgements about each risk of bias item for each included study.</p

    Participant characteristics.

    Full text link
    <p>Characteristics of the eighteen studies included in the qualitative synthesis: Population, eligibility criteria, baseline lipid levels, use of antiretroviral and lipid lowering drugs.</p><p>NR  =  not recorded.</p><p>LLM  =  lipid modification medication.</p><p>ART  =  antiretroviral therapy.</p><p>PIs  =  protease inhibitors.</p><p>RTV  =  ritonavir.</p><p>BMI  =  body mass index.</p><p>DM  =  diabetic.</p><p>CVD  =  cardiovascular disease.</p><p>HOMA-IR  =  insulin resistance.</p><p>Conversion factor used: x 0.01129 for mg/dl to mmol/l.</p

    Forest plot for effect of omega-3 supplementation on cholesterol levels (mmol/l).

    Full text link
    <p>Studies are ranked from low to high baseline cholesterol levels. Illustrates subgroup analysis of concurrent use of lipid lowering medication (LLM) on treatment effects of omega-3 supplementation on Cholesterol levels.</p

    Study characteristics.

    Full text link
    <p>Characteristics of the eighteen studies included in the qualitative synthesis: setting, sample size, intervention, control, and duration.</p>*<p>median value.</p>§<p>unpublished data.</p><p>¶ estimated, not reported by study.</p><p>n  =  number of participants analysed.</p><p>N  =  number randomised.</p><p>bd  =  twice daily.</p><p>tds  =  three times a day.</p><p>EPA  =  eicosapentaenoic acid.</p><p>DHA  =  docosahexaenoic acid.</p><p>NCEP  =  National Cholesterol Education Programme <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038121#pone.0038121-National1" target="_blank">[26]</a>.</p><p>wk  =  week.</p><p>Ax  =  assessment.</p><p>DEXA  =  dual-energy x-ray absorptiometry.</p

    Forest plot for effect of various dietary interventions on triglyceride levels (mmol/l).

    Full text link
    <p>Studies are ranked from low to high baseline triglyceride levels. Illustrates weighted mean difference in triglyceride levels between dietary intervention or omega-3 supplementation and control group.</p

    Adjusted odds ratios for combined risk factors and mortality<sup>a</sup>.

    Full text link
    a<p>Adjusting for sex, age (5 yrs group), education (no/primary, secondary, tertiary or higher), place of birth, housing (public housing, hut/shared, self owned, quarter/others) and job (sedentary, light, moderate, heavy, none).</p><p>*P<0.05, **P<0.01, ***P<0.001.</p
    corecore